SG11202006230YA - Acidic nanoparticles for restoration of autophagy - Google Patents
Acidic nanoparticles for restoration of autophagyInfo
- Publication number
- SG11202006230YA SG11202006230YA SG11202006230YA SG11202006230YA SG11202006230YA SG 11202006230Y A SG11202006230Y A SG 11202006230YA SG 11202006230Y A SG11202006230Y A SG 11202006230YA SG 11202006230Y A SG11202006230Y A SG 11202006230YA SG 11202006230Y A SG11202006230Y A SG 11202006230YA
- Authority
- SG
- Singapore
- Prior art keywords
- autophagy
- restoration
- nanoparticles
- acidic
- acidic nanoparticles
- Prior art date
Links
- 230000002378 acidificating effect Effects 0.000 title 1
- 230000004900 autophagic degradation Effects 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862619565P | 2018-01-19 | 2018-01-19 | |
US16/252,927 US10925975B2 (en) | 2018-01-19 | 2019-01-21 | Acidic nanoparticles for restoration of autophagy |
PCT/US2019/014410 WO2019144073A1 (en) | 2018-01-19 | 2019-01-21 | Acidic nanoparticles for restoration of autophagy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006230YA true SG11202006230YA (en) | 2020-07-29 |
Family
ID=67299787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006230YA SG11202006230YA (en) | 2018-01-19 | 2019-01-21 | Acidic nanoparticles for restoration of autophagy |
Country Status (10)
Country | Link |
---|---|
US (4) | US10925975B2 (he) |
EP (1) | EP3740243A4 (he) |
JP (1) | JP7293237B2 (he) |
KR (1) | KR102697202B1 (he) |
CN (1) | CN112004555B (he) |
BR (1) | BR112020014172A2 (he) |
CA (1) | CA3088371A1 (he) |
IL (1) | IL276035B2 (he) |
SG (1) | SG11202006230YA (he) |
WO (1) | WO2019144073A1 (he) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2539438A (en) * | 1947-04-01 | 1951-01-30 | American Cyanamid Co | Polymerized unsaturated tetrafluorosuccinate ester |
US5512651A (en) | 1994-07-29 | 1996-04-30 | Minnesota Mining And Manufacturing Company | Strong carboxylic acid functional polyurethane polymers and blends thereof used in magnetic recording media |
WO2006101538A2 (en) * | 2004-11-08 | 2006-09-28 | Cornell Research Foundation, Inc. | Andrographolide derivatives to treat viral infections |
US8657430B2 (en) * | 2010-10-08 | 2014-02-25 | Xerox Corporation | Curable phase change inks containing crystalline polyesters |
TWI572369B (zh) * | 2015-06-22 | 2017-03-01 | 國立清華大學 | 酸鹼應答型奈米微粒的製備並應用於製備促進抗癌藥物於腫瘤的傳輸與深層滲透之藥物的用途 |
WO2017062920A1 (en) * | 2015-10-07 | 2017-04-13 | Chopra Sunandini | Nanoparticles with ph triggered drug release |
-
2019
- 2019-01-21 JP JP2020537623A patent/JP7293237B2/ja active Active
- 2019-01-21 SG SG11202006230YA patent/SG11202006230YA/en unknown
- 2019-01-21 US US16/252,927 patent/US10925975B2/en active Active
- 2019-01-21 WO PCT/US2019/014410 patent/WO2019144073A1/en unknown
- 2019-01-21 CN CN201980009028.2A patent/CN112004555B/zh active Active
- 2019-01-21 BR BR112020014172-0A patent/BR112020014172A2/pt unknown
- 2019-01-21 IL IL276035A patent/IL276035B2/he unknown
- 2019-01-21 CA CA3088371A patent/CA3088371A1/en active Pending
- 2019-01-21 EP EP19741789.2A patent/EP3740243A4/en active Pending
- 2019-01-21 KR KR1020207023888A patent/KR102697202B1/ko active IP Right Grant
-
2022
- 2022-05-13 US US17/744,527 patent/US20220273812A1/en not_active Abandoned
- 2022-12-21 US US18/069,778 patent/US20230140315A1/en not_active Abandoned
-
2024
- 2024-04-12 US US18/634,632 patent/US20240252675A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019144073A1 (en) | 2019-07-25 |
CN112004555B (zh) | 2023-04-07 |
IL276035A (he) | 2020-08-31 |
IL276035B1 (he) | 2023-09-01 |
IL276035B2 (he) | 2024-01-01 |
JP2021511294A (ja) | 2021-05-06 |
CA3088371A1 (en) | 2019-07-25 |
US10925975B2 (en) | 2021-02-23 |
KR102697202B1 (ko) | 2024-08-20 |
US20230140315A1 (en) | 2023-05-04 |
KR20200118818A (ko) | 2020-10-16 |
US20190224336A1 (en) | 2019-07-25 |
EP3740243A1 (en) | 2020-11-25 |
AU2019210313A1 (en) | 2020-07-23 |
US20220273812A1 (en) | 2022-09-01 |
EP3740243A4 (en) | 2021-11-17 |
US20240252675A1 (en) | 2024-08-01 |
JP7293237B2 (ja) | 2023-06-19 |
CN112004555A (zh) | 2020-11-27 |
BR112020014172A2 (pt) | 2020-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL252507A0 (he) | אנטגוניסטים של מיוסטטין או אקטיבין לטיפול בניוון שרירים | |
EP3156032A4 (en) | Dental cement | |
GB201402070D0 (en) | Pharmaceutical compositions for the treatment of inflammatory disorders | |
IL251486B (he) | ערכת מבנה דנטלי זוויתי | |
IL271490A (he) | מכלול לשחזור שיניים | |
EP3267923A4 (en) | Guiding assembly for dental restoration procedures | |
EP3437622A4 (en) | CEMENT FOR DENTAL USE | |
TWI799397B (zh) | 用於治療高血壓之組合物 | |
EP3344256A4 (en) | COMPOSITIONS FOR THE TREATMENT OF JOINTS | |
IL269421A (he) | שיטת שחזור דנטלי | |
HK1196212A2 (en) | Brake mechanism of wheelchair | |
EP3200749A4 (en) | Methods for the treatment of peri-implantitis | |
GB201612043D0 (en) | Composition for treatment of disorders | |
EP3202404A4 (en) | Oral formulation of a-nor-5 androstane compound | |
HK1231482A1 (zh) | 用於治療炎症的作用於多種前列腺素受體的拮抗劑 | |
GB201702504D0 (en) | Hand rail for staircase | |
GB2554471B (en) | Dental prosthesis | |
IL260070B (he) | שיטה להכנה של 2-אריל-אתנולים מותמרים | |
GB201700390D0 (en) | Compounds for enhancing autophagy | |
IL276035B1 (he) | ננו–חלקיקים חומציים לשיחזור אוטופגיה | |
EP3322376A4 (en) | DIRECT TOOTHBRIDGE | |
PL3513777T3 (pl) | Sposób remineralizacji zębów | |
EP3437587A4 (en) | CONNECTING STRUCTURE FOR A TOOTH SUPPORT | |
ZA201908255B (en) | Treatment of oral candidiasis | |
AU201712438S (en) | Elbow for patient interface |